GAPPKB|Home

GAPP Knowledge Base (beta version)
An integrated, searchable knowledge base of genomic applications in practice and prevention (GAPP).

open here to see the full-contents:
GAPPKB|Home

The mutation spectrum of the SLC25A13 gene in Chin... [J Gastroenterol. 2010] - PubMed result

J Gastroenterol. 2010 Oct 7. [Epub ahead of print]

The mutation spectrum of the SLC25A13 gene in Chinese infants with intrahepatic cholestasis and aminoacidemia.
Fu HY, Zhang SR, Wang XH, Saheki T, Kobayashi K, Wang JS.

The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, 399 Wanyuan Road, Minhang District, Shanghai, 201102, People's Republic of China.

Abstract
BACKGROUND: SLC25A13 gene mutations cause citrin deficiency, which leads to neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). Information on the mutation spectrum of SLC25A13 in the Chinese population is limited. The aim of this study was to explore the mutation spectrum of the SLC25A13 gene in Chinese infants with intrahepatic cholestasis and various forms of aminoacidemia.

METHODS: Sequence analyses were performed on 39 infants with intrahepatic cholestasis and various forms of aminoacidemia. Novel mutations were subjected to homology and structural analyses. Western blots were performed when liver specimens available.

RESULTS: Genetic testing revealed the presence of SLC25A13 gene mutations (9 heterozygotes, 6 homozygotes and 13 compound heterozygotes) in 28 infants. Subsequent Western blot analysis revealed 22 cases of citrin deficiency, accounting for 56.4% of the 39 patients. Twelve types of mutations, including nine known mutations and three novel mutations, were found. Of the 49 mutated alleles, known ones include 851del4 (26 alleles, 53.1%), 1638ins23 (6 alleles, 12.2%), IVSl6ins3kb (3 alleles, 6.1%), IVS6+5G>A (2 alleles, 4.1%), E601K (2 alleles, 4.1%) and IVS11+1G>A, R184X, R360X and R585H (1 allele each, 2.0%). The three novel mutations were a splice site change (IVS6+1G>A), a deletion mutation (1092_1095delT) and a missense mutation (L85P), each in one allele.

CONCLUSIONS: The mutation spectrum of the SLC25A13 gene in a Chinese population of infants with intrahepatic cholestasis with various forms of aminoacidemia was found to be different from that of other population groups in East Asia. The SLC25A13 gene mutation is the most important cause of infantile intrahepatic cholestasis with various forms of aminoacidemia.

PMID: 20927635 [PubMed - as supplied by publisher]

The mutation spectrum of the SLC25A13 gene in Chin... [J Gastroenterol. 2010] - PubMed result

Vaccines and Related Biological Products Advisory Committee Update

* November 16-17, 2010: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda

Vaccines and Related Biological Products Advisory Committee > November 16-17, 2010: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda


** November 16-17, 2010: Vaccines and Related Biological Products Advisory Committee Meeting Briefing Document (PDF - 295KB)
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM231483.pdf



*** November 16-17, 2010: Vaccines and Related Biological Products Advisory Committee Roster (PDF - 37KB)
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM231514.pdf



**** November 16-17, 2010: Vaccines and Related Biological Products Advisory Committee Briefing Document Supplemental Biologics Licensing Application for Use in Anal Cancer Prevention (PDF - 2231KB)
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM231522.pdf

Research Activities, November 2010: Public Health Preparedness: Heart-lung machine may be considered for certain patients with H1N1 influenza with acute respiratory failure

Public Health Preparedness
Heart-lung machine may be considered for certain patients with H1N1 influenza with acute respiratory failure

Many young adults who contracted the novel 2009 influenza H1N1 virus were admitted to intensive care units with severe respiratory failure. A review of studies comparing different methods of getting oxygen into the lungs of such patients suggests that clinicians should consider extracorporeal membrane oxygenation (ECMO) along with other salvage therapies in patients failing conventional therapy. ECMO has been used for respiratory failure in different types of patients, but there are no clinical guidelines for its use in patients with the flu.

In this review of studies, the researchers found no randomized controlled trials of ECMO in flu patients. They did find an observational study of H1N1 flu patients in Australia and New Zealand that reported on 68 patients treated with ECMO, which uses a modified heart-lung machine (a mechanical pump to oxygenate and circulate the patient's blood), and 133 treated with mechanical ventilation (via a breathing tube) during winter in those countries. However, the two groups were not comparable because one group had more severe lung damage than the other.

To get additional information, the researchers combined the findings from three randomized trials of ECMO therapy conducted over 30 years, regardless of the origin of respiratory distress. This meta-analysis found a suggestive, but not statistically significant, reduction in deaths compared with patients not receiving ECMO. A more recent study randomly assigned 90 patients to ECMO therapy and 90 to conventional management (control group). The risk of death or severe disability at 6 months was a significant 31 percent less for the ECMO than the control group. However, the risk of death by 6 months just missed statistical significance. The study was funded in part by the Agency for Healthcare Research and Quality (HS18406).

More details are in "A systematic review to inform institutional decisions about the use of extracorporeal membrane oxygenation during the H1N1 influenza pandemic," by Matthew D. Mitchell, Ph.D., Mark E. Mikkelsen, M.D., M.S.C.E., Ingi Lee, M.D., M.S.C.E., and others in the June 2010 Critical Care Medicine 38(6), pp. 1398-1404.

Research Activities, November 2010: Public Health Preparedness: Heart-lung machine may be considered for certain patients with H1N1 influenza with acute respiratory failure

Research Activities, November 2010: Agency News and Notes: Human growth hormone shows promise in treating cystic fibrosis symptoms

Agency News and Notes
Human growth hormone shows promise in treating cystic fibrosis symptoms

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ). Cystic fibrosis is an inherited chronic multi-organ disease, caused by a defective gene, in which the body produces thick mucus that clogs the lungs and leads to life-threatening lung infections. The disease also makes it difficult for the pancreas to work, hampering the ability to absorb food. Common signs are salty tasting skin, difficulty breathing, chronic lung infections, poor weight gain, and shorter height. The disease typically is detected in childhood, stunting the patient's growth and usually leading to early death.

The report, Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis, finds that the use of human growth hormone increases height and weight, may improve lung functioning, and may strengthen the bones of patients with cystic fibrosis. Researchers found evidence suggesting that human growth hormone therapy reduces the need for hospitalizations, but could find no evidence that the therapy prolongs life or improves health-related quality of life. The use of human growth hormone was also found to raise blood sugar, which over time may lead to the development of diabetes in some patients.

"Patients with cystic fibrosis and their families have long looked for ways to manage this disease," said AHRQ Director Carolyn M. Clancy, M.D. "This report gives patients and their families excellent information that they can use, in consultation with their doctors, to make decisions about care."

The report was produced by the University of Connecticut/Hartford Hospital Evidence-based Practice Center for AHRQ. Results of the report were published online in the October issue of Pediatrics. Researchers examined published evidence from 53 unique studies of the effect of human growth hormone in cystic fibrosis patients as well as patients who did not have cystic fibrosis.

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis is the newest comparative effectiveness review from AHRQ's Effective Health Care Program. The Effective Health Care Program represents a leading Federal effort to compare alternative treatments for health conditions and make the findings public to help doctors, nurses, pharmacists, and others work together with patients to choose the most effective treatments.

In conjunction with the new report, AHRQ will soon publish plain-language summary guides about human growth hormone in cystic fibrosis for patients, clinicians, and policymakers. Summary guides on numerous clinical topics and other information and background on the Effective Health Care Program can be found at http://www.effectivehealthcare.ahrq.gov.

Research Activities, November 2010: Agency News and Notes: Human growth hormone shows promise in treating cystic fibrosis symptoms

Research Activities, November 2010: Women's Health: One-fifth of mothers do not receive recommended antenatal corticosteroids before delivery of premature infants

Women's Health
One-fifth of mothers do not receive recommended antenatal corticosteroids before delivery of premature infants

Strong evidence demonstrates that antenatal corticosteroids during preterm labor reduce the incidence of respiratory distress syndrome and other secondary complications associated with prematurity. Yet, 20 percent of eligible mothers failed to receive indicated antenatal corticosteroid therapy, according to a study at three New York City hospitals. Of these women, 43 percent delivered more than 2 hours after admission and 33 percent delivered more than 4 hours after admission, indicating sufficient time to have treated them.

The failure to administer recommended steroids was related strongly to how long after admission the delivery took place. Seventy-nine women delivered within 2 hours of admission and 73 percent of them did not receive the therapy. By contrast, only 8 percent of those who delivered between six and eight hours after admission did not receive recommended corticosteroids. This may be because the National Institutes of Health (NIH) Consensus Statement (1994) supporting the use of antenatal corticosteroids excludes from its recommendation women for whom immediate delivery was anticipated. Many of the women who delivered within 2 hours of admission were probably expected to deliver immediately, note the researchers.

In this study, women whose cervixes were at a more advanced stage were also less likely to receive steroids, suggesting that physicians chose to withhold steroids from women for whom they anticipated immediate delivery. They were generally correct (if imprecise), but wrong one-third of the time, note the researchers. They state that incorporating a physician's capacity to predict the immediate future regarding the time of delivery may have inadvertently subverted the capacity of the NIH guideline to guide practice. They recommend that the NIH guideline may have been more effectively implemented had the statement suggested that steroids should be provided to all eligible women who do not deliver within a specific time period, such as 1 hour after admission. The other factors associated with failure to receive recommended therapy were lack of prenatal care, longer gestation, advanced cervical exam, and intact membranes at admission.

The study included 515 women eligible for antenatal corticosteroids, of whom 70 percent were black or Hispanic. Most were insured through Medicaid or a Medicaid HMO. This study was supported, in part, by the Agency for Healthcare Research and Quality (HS10859).

See "Approaching NIH guideline recommended care for maternal-infant health: Clinical failures to use recommended antenatal corticosteroids" by Elizabeth A. Howell, M.D., Joanne Stone, M.D., Lawrence C. Kleinman, M.D., and others in the 2010 Maternal and Child Health Journal 14, pp. 430-436.
Research Activities, November 2010: Women's Health: One-fifth of mothers do not receive recommended antenatal corticosteroids before delivery of premature infants

Research Activities, November 2010: Outcomes/Effectiveness Research: Higher risk of death or heart attack in first 90 days after cardiac patients stop taking clopidogrel

Outcomes/Effectiveness Research
Higher risk of death or heart attack in first 90 days after cardiac patients stop taking clopidogrel

Earlier studies suggest that cardiac patients may experience problems after they stop taking the blood-thinning drug, clopidogrel, due to a potential rebound effect that may be caused by increased activation of blood platelets (cells involved in blood clotting). A new study has found a twofold increase in the risk of death or heart attack in the first 90 days after acute coronary syndrome patients stopped taking clopidogrel compared with later time intervals (91-360 days) and compared with patients remaining on clopidogrel therapy. It also demonstrated that the adverse outcomes occurred across multiple patient groups: women vs. men, percutaneous coronary intervention vs. medical therapy without stents, drug-eluting stents vs. bare metal stents, and duration of clopidogrel treatment before cessation (>6 months vs. <6 months).

The study also highlighted the incidence of bleeding events around the time of clopidogrel cessation (~7 percent) and showed that the clustering of adverse events was specific to clopidogrel discontinuation. The fact that there was a clustering of adverse events after stopping clopidogrel but not after stopping an angiotensin converting enzyme inhibitor medication (while staying on clopidogrel) suggests that the clustering of events is not a general effect of stopping medications, note the researchers.

Their findings suggest an urgent need to develop strategies to attenuate the observed clustering of events after the end of a prescribed clopidogrel treatment course. The study population included 1,656 patients with postacute coronary syndrome patients who stopped clopidogrel and had been event-free before stopping the drug. This study was funded by the Agency for Healthcare Research and Quality (Contract No. 290-05-0033).

See "Adverse events after stopping clopidogrel in post acute coronary syndrome patients: Insights from a large integrated healthcare delivery system" by P. Michael Ho, M.D., Ph.D., Thomas T. Tsai, M.D., M.Sc., Tracy Y. Wang, M.D., M.H.S., and others in Circulation: Cardiovascular Quality and Outcomes 3, pp. 303-308, 2010.

Research Activities, November 2010: Outcomes/Effectiveness Research: Higher risk of death or heart attack in first 90 days after cardiac patients stop taking clopidogrel

Research Activities, November 2010: Outcomes/Effectiveness Research: Clopidogrel increases bleeding risk in cardiac patients with drug-eluting stents

Outcomes/Effectiveness Research
Clopidogrel increases bleeding risk in cardiac patients with drug-eluting stents

Patients suffering from a blockage in their coronary arteries usually undergo coronary angioplasty. In this procedure, a balloon-tipped catheter is inserted through the groin into the blocked artery along with a drug-eluting stent (wire mesh tube), which expands when the balloon is inflated to provide a scaffold to keep the coronary artery open. The stent remains once the balloon catheter is withdrawn. After this procedure, patients may be placed on clopidogrel, a blood-thinning agent, to prevent clots from forming on the stent. However, a new study finds that patients placed on clopidogrel have an increased risk of bleeding, although their risk for a heart attack decreases.

A total of 7,689 patients were evaluated for this study. All had received drug-eluting stents, with just under half (49.1 percent) receiving clopidogrel for more than 6 months. Patients were followed for up to 18 months for signs of major bleeding, a heart attack, or death. Particular attention was paid to the time interval from 0 to 6 months, the recommended time for clopidogrel therapy from the drug's manufacturer. After a mean follow-up of 418 days, 3.6 percent of patients experienced a major bleeding event. The percentage of patients who suffered a heart attack or died was 3.7 percent and 2.9 percent, respectively. Even when the researchers adjusted for various factors, there was still a significant association between clopidogrel and an increase in major bleeding for all time intervals. These included 0 to 6 months, 7 to 12 months, and 13 to 18 months. However, patients on clopidogrel had a decreased risk of having a heart attack for all time intervals while on the therapy. There was also a decrease in death rate for clopidogrel patients during the 7- to 12-month time interval.

The researchers call for more randomized clinical trials to determine the optimal time patients should be on clopidogrel in order to reduce bleeding risks and increase the benefits of therapy. The study was supported in part by the Agency for Healthcare Research and Quality (HS00331).

See "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation," by Thomas T. Tsai, M.D., M.Sc., P. Michael Ho, M.D., Ph.D., Stanley Xu, Ph.D., and others in the June 2010 Circulation Cardiovascular Interventions 3, pp. 230-235.

Research Activities, November 2010: Outcomes/Effectiveness Research: Clopidogrel increases bleeding risk in cardiac patients with drug-eluting stents

Ancestry and Disease in the Age of Genomic Medicine — NEJM

Ancestry and Disease in the Age of Genomic Medicine
Charles N. Rotimi, Ph.D., and Lynn B. Jorde, Ph.D.
N Engl J Med 2010; 363:1551-1558October 14, 2010

Abstract

From the Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD (C.N.R.); and the Department of Human Genetics, University of Utah Health Sciences Center, Salt Lake City (L.B.J.).

Address reprint requests to Dr. Rotimi at the National Institutes of Health Center for Research on Genomics and Global Health, 12 South Dr., MSC 5635, Bethesda, MD 20851-5635, or at rotimic@mail.nih.gov.

Ancestry and Disease in the Age of Genomic Medicine — NEJM

Being More Realistic about the Public Health Impact of Genomic Medicine

PLoS Med. 2010 Oct 12;7(10). pii: e1000347.
Being more realistic about the public health impact of genomic medicine.

Hall WD, Mathews R, Morley KI.

University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Queensland, Australia. w.hall@uq.edu.au

PMID: 20967240 [PubMed - in process]PMCID: PMC2953533
Free PMC Article
Being More Realistic about the Public Health Impact of Genomic Medicine

Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making? - Rämet - 2010 - Pediatric Pulmonology - Wiley Online Library

Pediatr Pulmonol. 2010 Oct 20. [Epub ahead of print]
Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?

Rämet M, Korppi M, Hallman M.

Department of Pediatrics, Tampere University Hospital, Tampere, Finland.

Abstract

Respiratory syncytial virus (RSV) causes respiratory tract infections, especially among young infants. Practically, all infants are infected during epidemics and the clinical presentation ranges from subclinical to fatal infection. Known risk factors for severe RSV infection include prematurity, age of <2 months, underlying chronic lung or heart diseases, serious neurological or metabolic disorders, immune deficiency (especially a disorder of cellular immunity), crowded living conditions, and indoor smoke pollution. Twin studies indicate that host genetic factors affect susceptibility to severe RSV infection. Pattern recognition receptors (PRRs) are the key mediators of the innate immune response to RSV. In the distal respiratory tract, RSV is recognized by the transmembrane Toll-like receptor 4 (TLR4) and adapter proteins, which lead to production of proinflammatory cytokines and subsequent activation of the adaptive immune response. Surfactant proteins A and D are able to bind both RSV and TLR4, modulating the inflammatory response. Genetic variations in TLR4, SP-A, and SP-D have been associated with the risk of severe RSV bronchiolitis, but the results have varied between studies. Both the homozygous hyporesponsive 299Gly genotype of TLR4 and the non-synonymous SP-A and SP-D polymorphism influence the presentation of RSV infection. The reported relative risks associated with these markers are not robust enough to justify clinical use. However, current evidence indicates that innate immune responses including pattern recognition receptors (PRRs) and other components in the distal airways and airspaces profoundly influence the innate immune responses, playing a key role in host resistance to RSV in young infants. This information is useful in guiding efforts to develop better means to identify the high-risk infants and to treat this potentially fatal infection effectively. Pediatr Pulmonol. © 2010 Wiley-Liss, Inc.

PMID: 20963841 [PubMed - as supplied by publisher]
Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making? - Rämet - 2010 - Pediatric Pulmonology - Wiley Online Library

Individual variability in the disposition of and r... [Pharmacol Ther. 2010] - PubMed result

Pharmacol Ther. 2010 Oct 18. [Epub ahead of print]
Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond.

Xie HG, Chen SL, Hu ZY, Zhang JJ, Ye F, Zou JJ.

Hospital Central Laboratory, Nanjing First Hospital Affiliated to Nanjing Medical University, and Nanjing Cardiovascular Hospital, Nanjing, Jiangsu, China; Department of Clinical Pharmacology, Nanjing First Hospital Affiliated to Nanjing Medical University, and Nanjing Cardiovascular Hospital, Nanjing, Jiangsu, China.

Abstract

The widespread use of clopidogrel alone or in combination with aspirin has significantly benefited patients with acute coronary syndrome who are managed medically or by percutaneous coronary intervention and stent implantation, greatly improving their survival. Emerging data have documented that the clopidogrel response may vary from person to person and even from disease to disease, and that genetic and nongenetic factors contribute to that variability. Genetic polymorphisms affecting clopidogrel metabolic bioactivation and platelet function may be contributory, each exerting a small effect. Contributions from CYP2C19 *2, *3 and *17, CYP2C9 *2 and *3, MDR1*2, and functional variants in the genes encoding platelet membrane receptors and intracellular signaling proteins are involved, and other genetic factors remain to be identified. In addition, nongenetic factors may be involved, such as ethnicity, gender, age, body weight, co-existing diseases, drug-drug interactions, and other factors to be determined. Each piece of the puzzle would be useful to delineate identified knowledge gaps and to determine future research needs for the risk prediction of fatal complications associated with inadequate clopidogrel therapy in patient care.
Copyright © 2010. Published by Elsevier Inc.

PMID: 20965214 [PubMed - as supplied by publisher]
Individual variability in the disposition of and r... [Pharmacol Ther. 2010] - PubMed result

Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation — J. Natl. Cancer Inst.

J Natl Cancer Inst. 2010 Oct 13. [Epub ahead of print]
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation.

Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.

Affiliations of authors: Division of Cancer Control and Population Sciences (ANF, LBS, SAN, RB-B), Medical Oncology Branch, Center for Cancer Research (WDF), Division of Cancer Epidemiology and Genetics (NR), Division of Cancer Treatment and Diagnosis (JHD), and Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (LMM); Health Services Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (ALP); Center for Drug Safety, University of Maryland School of Pharmacy, Baltimore, MD (SRWS); Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA (MJK); Division of Clinical Pharmacology, Mayo Clinic College of Medicine, Rochester, MN (RMW); Clinical Sciences, Cancer Research Center, University of Chicago Medical Center, Chicago, IL (MJR); UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC (HLM); Medco Health Solutions, Inc, Franklin Lakes, NJ (RSE); Center for Genomic Medicine, Duke Institute for Genome Sciences & Policy, Duke University, Durham, NC (GSG); Section of Hematology-Oncology, University of Chicago Medical Center, Chicago, IL (RLS); Ontario Cancer Institute, Princess Margaret Hospital, University of Toronto, Toronto, Ontario (GL); Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN (DAF); Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany (CMU); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (CMU); The Center for Health Research, Kaiser Permanente, Atlanta, GA (RLD); Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (LJL, IZ); Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD (GR); Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY (CBA); Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN (MVR); Division for Clinical Research Resources, National Center for Research Resources, National Institutes of Health, Bethesda, MD (HX); University of Texas M.D. Anderson Cancer Center, Houston, TX (MRS).
Abstract

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.

PMID: 20944079 [PubMed - as supplied by publisher]
Free Article
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation — J. Natl. Cancer Inst.

Chipping Away the ‘Missing Heritability’: GIANT Steps Forward in the Molecular Elucidation of Obesity – but Still Lots to Go

Obes Facts. 2010 Oct;3(5):294-303. Epub 2010 Oct 15.
Chipping Away the 'Missing Heritability': GIANT Steps Forward in the Molecular Elucidation of Obesity - but Still Lots to Go.

Hebebrand J, Volckmar AL, Knoll N, Hinney A.

Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Essen, Germany.

Abstract

Although heritability of human body weight is assumed to be high, only a small fraction of the variance can as yet be attributed to molecular genetic factors. Single monogenic forms of obesity have been identified. Functionally relevant coding mutations in the melanocortin-4 receptor gene occur in 1-6% of extremely obese children and adolescents and thus represent the most common major gene effect. Genome-wide association studies (GWAS) had previously identified 14 obesity loci with genome-wide significant (p < 5 x 10-8) associations. Many of the respective genes are expressed in the central nervous system. The GIANT (Genetic Investigation of ANtropometric Traits) Consortium has now performed a meta-analysis of GWAS data based on 123,865 individuals of European ancestry followed by confirmatory analyses for the 42 best independent loci in up to 125,931 independent individuals (Speliotes et al: Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index. Nature Genetics; epub October 2010 [1]). Apart from confirming the 14 known loci, 18 novel BMI-associated loci (p < 5 x 10-8) were identified. Several of the new loci point to genes involved in key hypothalamic pathways of energy balance. The identified variants mostly have small to very small effect sizes; only 1-2% of the BMI variance is explained. Currently, a consensus explanation for this 'missing heritability' in complex diseases has not yet emerged.
Copyright © 2010 S. Karger AG, Basel.

PMID: 20975295 [PubMed - in process]
Chipping Away the ‘Missing Heritability’: GIANT Steps Forward in the Molecular Elucidation of Obesity – but Still Lots to Go

Sex hormone receptor gene polymorphisms and migrai... [Cephalalgia. 2010] - PubMed result

Cephalalgia. 2010 Nov;30(11):1306-28. Epub 2010 May 4.
Sex hormone receptor gene polymorphisms and migraine: a systematic review and meta-analysis.

Schürks M, Rist PM, Kurth T.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215-1204, USA.
mschuerks@rics.bwh.harvard.edu

Abstract

BACKGROUND: Data on the association between sex hormone receptor polymorphisms and migraine are conflicting.

METHODS: We performed a systematic review and meta-analysis on this topic searching for studies published until August 2009. For each study, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) assuming additive, dominant, and recessive genetic models. We then calculated pooled ORs and 95% CIs.

RESULTS AND CONCLUSION: Among the seven genes targeted, four variants were investigated in multiple studies. Effect estimates from an additive model suggest that the ESR-1 594 G>A (pooled OR 1.37; 95% CI 1.02-1.83) and ESR-1 325 C>G (pooled OR 1.16; 95% CI 1.03-1.32) variants are associated with any migraine. This pattern does not differ between migraine with and without aura. In contrast, the ESR-1 Pvu II C>T and PGR PROGINS insert polymorphism do not appear to be associated with migraine. Results were driven by studies among Caucasians and may differ in other ethnic groups.

PMID: 20959426 [PubMed - in process]
Sex hormone receptor gene polymorphisms and migrai... [Cephalalgia. 2010] - PubMed result

Expert Reviews - Expert Review of Molecular Diagnostics - 10(7):857 - Summary

Expert Rev Mol Diagn. 2010 Oct;10(7):857-61.
Genes associated with multiple sclerosis: 15 and counting.

Habek M, Brinar VV, Borovečki F.

School of Medicine, University of Zagreb, Croatia.

Comment on:

* Genes Immun. 2010 Jul;11(5):397-405.

Abstract

Evaluation of: The International Multiple Sclerosis Genetics Consortium (IMSGC). IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun. 11(5), 397-405 (2010). Multiple sclerosis (MS) develops in genetically susceptible populations as a result of environmental exposures, and discovering these genetic and/or environmental factors will provide fundamental new insights into the pathogenesis, diagnosis and treatment of this disabling disease. With the introduction of genome-wide association studies, the number of genes found to be associated with MS has increased rapidly. In all of these genes, in a study by the International Multiple Sclerosis Genetics Consortium, the classic MS risk locus, HLA-DRB1, stood out with remarkably strong statistical significance, but they also identified 12 other loci and/or genes associated with MS. However, all of these alleles have a very modest odds ratio and they explain approximately 3% of the variance in MS risk. Recently, the International Multiple Sclerosis Genetics Consortium provided evidence for three new loci that show significant association at a genome-wide level: RGS1, IL12A and MPHOSPH9/CDK2AP1. In this article, we will review the three newly discovered susceptibility loci and the implications of genome-wide association studies in MS on clinical practice.

PMID: 20964605 [PubMed - in process]
Expert Reviews - Expert Review of Molecular Diagnostics - 10(7):857 - Summary

5-HTTLPR polymorphism in the serotonin transporter... [Cephalalgia. 2010] - PubMed result

Cephalalgia. 2010 Nov;30(11):1296-305. Epub 2010 Mar 26.
5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis.

Schürks M, Rist PM, Kurth T.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215-1204, USA.
mschuerks@rics.bwh.harvard.edu

Abstract

BACKGROUND AND METHODS: Data on the association between the SLC6A4 5-HTTLPR polymorphism and migraine are conflicting. We performed a systematic review and meta-analysis among studies published up to September 2009. For each study with genotype information, we calculated odds ratios (OR) and 95% confidence intervals (CI) assuming additive, dominant, and recessive genetic models. We then calculated pooled ORs and 95% CIs.

RESULTS: Among the ten studies identified there was no overall association between the polymorphism and any migraine for Europeans or Asians. However, European women carrying the S allele had an increased risk for any migraine (dominant model: pooled OR=2.02; 95% CI 1.24-3.28). Results among Europeans further suggested an increased risk for migraine with aura among carriers of the S/S genotype (recessive model: pooled OR=1.41; 95% CI 0.83-2.40).

CONCLUSIONS: While our results indicate no overall association between the SLC6A4 5-HTTLPR polymorphism and migraine among Europeans and Asians, gender and migraine aura status may have modifying roles among Europeans.

PMID: 20959425 [PubMed - in process]

5-HTTLPR polymorphism in the serotonin transporter... [Cephalalgia. 2010] - PubMed result

Host Genetics and HIV-1: The Final Phase?

PLoS Pathog. 2010 Oct 14;6(10):e1001033.
Host Genetics and HIV-1: The Final Phase?

Fellay J, Shianna KV, Telenti A, Goldstein DB.

Center for Human Genome Variation, Duke University School of Medicine, Durham, North Carolina, United States of America.

Abstract

This is a crucial transition time for human genetics in general, and for HIV host genetics in particular. After years of equivocal results from candidate gene analyses, several genome-wide association studies have been published that looked at plasma viral load or disease progression. Results from other studies that used various large-scale approaches (siRNA screens, transcriptome or proteome analysis, comparative genomics) have also shed new light on retroviral pathogenesis. However, most of the inter-individual variability in response to HIV-1 infection remains to be explained: genome resequencing and systems biology approaches are now required to progress toward a better understanding of the complex interactions between HIV-1 and its human host.

PMID: 20976252 [PubMed - in process]PMCID: PMC2954832
Free PMC Article
Host Genetics and HIV-1: The Final Phase?

Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases.

Indian J Med Res. 2010 Oct;132:363-78.
Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases.

Anoop S, Misra A, Meena K, Luthra K.

Department of Environmental Sciences, Bharathiar University, Coimbatore, India.

Abstract

The role of apolipoprotein E (apo E) in lipid metabolism and cholesterol transport is well established. About 14 per cent of the variation in plasma cholesterol levels is attributed to polymorphisms in APO E gene (APO E). APO E consists of three common alleles, designated as ε2, ε3 and ε4 which code for E2, E3 and E4 proteins respectively resulting in three homozygous (E2/E2, E3/E3, E4/E4) and three heterozygous (E3/E2, E4/E2 and E4/E3) phenotypes. Different populations studied worldwide inherit variable frequencies of the APO E alleles and genotypes, with the most frequent allele being ε3.The ε4 allele has been consistently shown to be associated with Alzheimer's disease, coronary heart disease and cerebrovascular disorders. In this review, we have discussed the role of APO E polymorphisms in cerebrovascular and coronary heart diseases. The status of APO E polymorphisms and their disease associations in Asian Indians besides, other populations has also been discussed. Further, studies elucidating the pathophysiology of apo E deficiency conducted in knock-out mice have been reviewed.

PMID: 20966513 [PubMed - in process]
Free Article
4.pdf (Objeto application/pdf)

Apolipoprotein E polymorphism in cerebrovascular &... [Indian J Med Res. 2010] - PubMed result

A multilocus genetic risk score for coronary heart... [Lancet. 2010] - PubMed result

Lancet. 2010 Oct 23;376(9750):1393-400.
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses.

Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S.

Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. samuli.ripatti@fi mm.fi

Comment in:

* Lancet. 2010 Oct 23;376(9750):1366-7.

Abstract

BACKGROUND: Comparison of patients with coronary heart disease and controls in genome-wide association studies has revealed several single nucleotide polymorphisms (SNPs) associated with coronary heart disease. We aimed to establish the external validity of these findings and to obtain more precise risk estimates using a prospective cohort design.

METHODS: We tested 13 recently discovered SNPs for association with coronary heart disease in a case-control design including participants differing from those in the discovery samples (3829 participants with prevalent coronary heart disease and 48,897 controls free of the disease) and a prospective cohort design including 30,725 participants free of cardiovascular disease from Finland and Sweden. We modelled the 13 SNPs as a multilocus genetic risk score and used Cox proportional hazards models to estimate the association of genetic risk score with incident coronary heart disease. For case-control analyses we analysed associations between individual SNPs and quintiles of genetic risk score using logistic regression.

FINDINGS: In prospective cohort analyses, 1264 participants had a first coronary heart disease event during a median 10·7 years' follow-up (IQR 6·7-13·6). Genetic risk score was associated with a first coronary heart disease event. When compared with the bottom quintile of genetic risk score, participants in the top quintile were at 1·66-times increased risk of coronary heart disease in a model adjusting for traditional risk factors (95% CI 1·35-2·04, p value for linear trend=7·3×10(-10)). Adjustment for family history did not change these estimates. Genetic risk score did not improve C index over traditional risk factors and family history (p=0·19), nor did it have a significant effect on net reclassification improvement (2·2%, p=0·18); however, it did have a small effect on integrated discrimination index (0·004, p=0·0006). Results of the case-control analyses were similar to those of the prospective cohort analyses.

INTERPRETATION: Using a genetic risk score based on 13 SNPs associated with coronary heart disease, we can identify the 20% of individuals of European ancestry who are at roughly 70% increased risk of a first coronary heart disease event. The potential clinical use of this panel of SNPs remains to be defined.

FUNDING: The Wellcome Trust; Academy of Finland Center of Excellence for Complex Disease Genetics; US National Institutes of Health; the Donovan Family Foundation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID: 20971364 [PubMed - in process]
A multilocus genetic risk score for coronary heart... [Lancet. 2010] - PubMed result

Abstract | Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery

BMC Womens Health. 2010 Oct 20;10(1):28. [Epub ahead of print]
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Salhab M, Bismohun S, Mokbel K.

Abstract

ABSTRACT:

BACKGROUND: Women who have inherited mutations in the BRCA1 or BRCA2 genes have substantially elevated risks of breast and ovarian cancer. Mutation carriers have various options, including extensive and regular surveillance, chemoprevention and risk-reducing surgery. The aim of this review is to provide an up-to-date analysis and to subsequently summarise the available literature in relation to risk-reducing strategies, with a keen focus on prophylactic surgery.

METHODS: The literature review is facilitated by Medline and PubMed databases. The cross-referencing of the obtained articles was used to identify other relevant studies.

RESULTS: Prophylactic surgery (bilateral mastectomy, bilateral salpingo-oophorectomy or a combination of both procedures) has proved to be the most effective risk-reducing strategy. There are no randomised controlled trials able to demonstrate the potential benefits or harms of prophylactic surgery; therefore, the evidence has been derived from retrospective and short follow-up prospective studies, in addition to hypothetical mathematical models. Based on the current knowledge, it is reasonable to recommend prophylactic oophorectomy for BRCA1 or BRCA2 mutation carriers when childbearing is completed in order to reduce the risk of developing breast and ovarian cancer. In addition, women should be offered the options of rigorous breast surveillance, chemoprevention with anti-oestrogens--especially for carriers of BRCA2--or bilateral prophylactic mastectomy.

CONCLUSION: The selection of the most appropriate risk-reducing strategy is not a straightforward task. The impact of risk-reducing strategies on cancer risk, survival, and overall quality of life are the key criteria considered for decision-making. Notably, various other factors should be taken into consideration when evaluating individual mutation carriers' individual circumstances, namely woman's age, morbidity, type of mutation, and individual preferences and expectations. Although prospective randomised controlled trials concerned with examining the various interventions in relation to the woman's age and type of mutation are needed, randomisation is extremely difficult and rather deemed unethical given the current available evidence from retrospective studies.

PMID: 20961453 [PubMed - as supplied by publisher]
Free Article
Abstract | Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery

From genomic landscapes to personalized cancer management—is there a roadmap? - Swanton - 2010 - Annals of the New York Academy of Sciences - Wiley Online Library

Ann N Y Acad Sci. 2010 Oct;1210(1):34-44. doi: 10.1111/j.1749-6632.2010.05776.x.
From genomic landscapes to personalized cancer management-is there a roadmap?

Swanton C, Caldas C.

Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom. Royal Marsden Hospital, Department of Medicine, Breast Unit, Sutton, United Kingdom. Department of Oncology, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom. Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom.

Abstract

Despite rapid progress in annotating the human genome, progress in biomarker discovery has been limited, in part, due to the restricted adoption of biomarker analysis in clinical trials. In this short review we present a roadmap to drive progress in the field of personalized cancer management and patient stratification. We suggest that improved understanding of disease biology and drug response in advance of clinical trial design would enable novel biomarkers to be identified and prospectively evaluated during early phase trials; there will also be value in banked material from completed clinical trials to identify and validate biomarkers. Such progress requires standardized tissue collection protocols, novel bioinformatics strategies integrated with functional genomics analysis, and next generation sequencing technologies. We argue that the failure to adopt these methods rapidly into clinical trial design will increase late stage drug attrition, waste trial resources, and risk patient harm within unselected cohorts.
© 2010 New York Academy of Sciences.

PMID: 20973797 [PubMed - in process]
From genomic landscapes to personalized cancer management—is there a roadmap? - Swanton - 2010 - Annals of the New York Academy of Sciences - Wiley Online Library

Breast Cancer Surgery Trend Changes Since the Intr... [Ann Surg Oncol. 2010] - PubMed result

Ann Surg Oncol. 2010 Oct 23. [Epub ahead of print]
Breast Cancer Surgery Trend Changes Since the Introduction of BRCA1/2 Mutation Screening: A Retrospective Cohort Analysis of 158 Mutation Carriers Treated at a Single Institution.

Mislowsky A, Domchek S, Stroede C, Bergey MR, Sonnad SS, Wu L, Tchou J.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Abstract

BACKGROUND: Bilateral mastectomy in women diagnosed with unilateral breast cancer is on the rise in the USA. One contributing factor is increased awareness of contralateral breast cancer risk. Positive testing for deleterious mutation in BRCA1/2 is a concrete measure of this contributing factor. We hypothesize that breast cancer surgery trend change is temporally associated with the introduction of BRCA1/2 genetic testing around 1996.

METHODS: Our study cohort included 158 BRCA1 or BRCA2 mutation carriers diagnosed with unilateral breast cancer between 1963 and 2009. Mutation carriers with ovarian cancer or bilateral breast cancer were excluded. Breast surgery and breast reconstruction surgery trends were analyzed according to year of breast cancer diagnosis or when bilateral mastectomy was performed, respectively.

RESULTS: Surgery trends changed significantly over time. We observed a significant drop in the rate of unilateral mastectomy (P < 0.001) after the period 1996-2000, and the rate of bilateral mastectomy appears to be on the rise, up to 30.3% between 2006 and 2009. Breast reconstruction trends also changed significantly over time, with a significant rise in the rate of free flap reconstruction to 58.8% between 2006 and 2009.

CONCLUSIONS: Our results demonstrated a significant decrease in unilateral mastectomy with a rise in bilateral mastectomy after the period 1996-2000, a period which encompassed the year when genetic testing of the two BRCA1/2 genes became commercially available, hence supporting our hypothesis.

PMID: 20972632 [PubMed - as supplied by publisher]
Breast Cancer Surgery Trend Changes Since the Intr... [Ann Surg Oncol. 2010] - PubMed result

A multi-stage genome-wide association study of bla... [Nat Genet. 2010] - PubMed result

Nat Genet. 2010 Nov;42(11):978-84. Epub 2010 Oct 24.
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ.

[1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. [2] These authors contributed equally to this work.

Abstract

We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10(-12)) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10(-11)) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10(-7)) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10(-11)) and a tag SNP for NAT2 acetylation status (P = 4 × 10(-11)), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis.

PMID: 20972438 [PubMed - in process]
A multi-stage genome-wide association study of bla... [Nat Genet. 2010] - PubMed result

EL BIRUNI: CIENCIAS MÉDICAS NEWS - DIRECTORIO DE DOCUMENTOS EDITADOS EN OCTUBRE 2010 [*]

domingo 31 de octubre de 2010
EL BIRUNI: DIRECTORIO DE DOCUMENTOS EDITADOS EN OCTUBRE 2010 [*]

CIENCIAS MÉDICAS NEWS
CIENCIAS MÉDICAS APLICADAS
RESEARCH & CLINICAL DEVELOPMENT

► http://elbiruniblogspotcom.blogspot.com
CIENCIAS MÉDICAS NEWS

► http://saludequitativa.blogspot.com
GESTIÓN EN SALUD PÚBLICA

► http://herenciageneticayenfermedad.blogspot.com

Consultas acumuladas desde enero 2009 a la fecha: 254.778
Consultas totales conjuntas (todos los blogs): 1.050.000

Discriminadas como sigue:
1. ARGENTINA: 39.131 [15,4%]
2. ESPAÑA: 37.211 [14,6%]
3. MÉXICO: 34.881 [13,7%]
4. U.S.A.: 29.416 [11,5%]
5. COLOMBIA: 15.278 [ 6.0%]
6. PERÚ: 14.265[ 5,6%]
7. VENEZUELA: 13.416 [ 5,3%]
8. CHILE: 9.106 [ 3,6%]
9. ECUADOR: 6.048 [ 2,4%]
10. BOLIVIA: 4.521 [ 1,8%]
11. LOS DEMÁS: 51.505 [20.2%]
Total de consultas: 254.778

Documentos del mes de OCTUBRE: 583
Documentos acumulados en 2010: 5.048
Documentos editados desde el inicio del blog: 9.553




Archivo del blog

▼  2010 (5048)
▼  octubre (583)

Complementary and Alternative Therapies for Back P...
Safety Alerts for Human Medical Products > Methotr...
Inhaled Nitric Oxide in Preterm Infants: Structure...
Promising New 'Antigene' Therapy
Clear New Insights into the Genetics of Depression...
ESHRE publishes new PGD guidelines
Pregnancy outcome affected by immune system genes
Neurogenetics Research Sheds Light On The Causes O...
Risk Gene For Severe Heart Disease Discovered
Gene Therapy Can Reverse Life-Threatening Pulmonar...
No association between KIF6 Trp719Arg polymorphism...
Newfoundland researchers crack the genetic code of...
Fredericksburg.com - Rare gene mutations raise ris...
Unique database of cancer -- designed to personali...
Knowledge Of Genetic Cancer Risks Often Dies With ...
Deadly Pancreatic Cancer Develops Much More Slowly...
FDA Approves Teflaro for Bacterial Infections
CDC- Cancer - Advisory Committee on Breast Cancer ...
Injectable Methotrexate Recall | Methotrexate Arth...
Independent panel discourages routine use of treat...
Cancer’s hiding spots revealed
DNA Damage-Mediated Induction of a Chemoresistant ...
About the Center for Drug Evaluation and Research ...
Pancreatic Cancer Surprisingly Slow to Arise: Stud...
New Drug Shows Promise Against Certain Lung Cancer...
H1N1 Flu Linked to Surge in Pneumonia Complication...
FDA approves Latuda to treat schizophrenia in adul...
Teens Should Get Meningitis Booster Shot: CDC Pane...
NIH introduces Images, a database of images in bio...
CDC - Injury: Concussion - Sports: NFL and Young A...
Notes from the Field: Vibrio mimicus Infection fro...
Rapid Diagnostic Tests for Malaria --- Haiti, 2010...
Global Routine Vaccination Coverage, 2009
November Is American Diabetes Month
Incidence of End-Stage Renal Disease Attributed to...
LETOSPIROSIS, BROTE EPIDÉMICO, PROPAGACIÓN - CENTR...
ENTEROBACTERIAS, GEN NDM-1, PRIMEROS CASOS - CHINA...
KPC, MUERTES, PROPAGACIÓN RÁPIDA - BRASIL (03)
CÓLERA, MISONERA, VUELO INTERNACIONAL: SOSPECHA -...
Cholera Outbreak --- Haiti, October 2010
A map of human genome variation from population-sc...
Genomics: The search for association : Nature : Na...
Genomics: In search of rare human variants : Natur...
1000 Genomes Project reveals human variation : Nat...
DASATINIB . FDA approves additional medical indica...
National Guideline Clearinghouse | Prevention of p...
National Guideline Clearinghouse | Management of u...
National Guideline Clearinghouse | Management of a...
National Guideline Clearinghouse | Tenofovir disop...
National Guideline Clearinghouse | Rituximab for t...
National Guideline Clearinghouse | Recommended imm...
National Guideline Clearinghouse | Guidelines for ...
National Guideline Clearinghouse | American Societ...
National Guideline Clearinghouse | American Societ...
National Guideline Clearinghouse | Unintended weig...
National Guideline Clearinghouse | Chronic obstruc...
Wild chimpanzees infected with 5 Plasmodium specie...
Case Fatality Proportion of Deaths for Infection w...
AHRQ News and Numbers: Stroke Survival Greater for...
Yersinia pestis DNA Sequences in Late Medieval Ske...
Vibrio cholerae O1 Variant with Reduced Susceptibi...
Geographic Expansion of Baylisascaris procyonis Ro...
Mycobacterium heckeshornense Infection in HIV-infe...
Fatal Avian Influenza (H5N1) Infection in Human, C...
Shigella spp. Antimicrobial Drug Resistance, Papua...
NCCN 16th Annual Conference - Event Summary | Onli...
NCCN 2010 Congress Series: Respiratory Tract Cance...
CDC - Blogs - Safe Healthcare – Organ transplant s...
Products - Data Briefs - Number 48 - October 2010
U.S. cautions on mixed use of Roche, Abbott HIV dr...
GI Endoscopy Complication Rates Higher Than Suspec...
From Touchpad to Thought-pad?, October 27, 2010 Ne...
1000 Genomes Project publishes analysis of complet...
Use Anemia Drugs for Cancer Patients With Caution,...
Two Clusters of HIV-1 Infection, Rural Idaho, USA,...
Pandemic (H1N1) 2009 and Oseltamivir Resistance in...
Acute Encephalopathy and Pandemic (H1N1) 2009 | CD...
Oseltamivir-Resistant Pandemic (H1N1) 2009 Treated...
Enteric Viruses in Ready-to-Eat Packaged Leafy Gre...
The Persistence of Influenza Infection | CDC EID
Smallpox Zero: An Illustrated History of Smallpox ...
Conservation of Hendra Virus Isolates | CDC EID
Enterovirus 71 with CNS Involvement | CDC EID
HEV Infection in Homeless Persons | CDC EID
E. coli in Neonatal Care Unit | CDC EID
S. enterica Serovar Infantis, Israel | CDC EID
Streptococcus pneumoniae Serotype 6D, South Korea ...
Reassortment in Pandemic (H1N1) 2009 Virus | CDC E...
Pandemic (H1N1) 2009 Virus and Cats | CDC EID
Media Availability: NIH scientists discover secret...
Transmissible Spongiform Encephalopathies Advisory...
Severe sepsis associated with later cognitive, phy...
Universal robotic gripper based on the jamming of ...
EPICLIN ESTUDIO - 2 de cada 3 pacientes con cáncer...
Soluble plasma HLA peptidome as a potential source...
Dengue Virus, Tanzania and Côte d'Ivoire | CDC EID...
Comparison of Norovirus Survey Methods, Oregon | C...
Lymphogranuloma Venereum C. trachomatis Strains | ...
Enterovirus 75 Encephalitis in Children - Southern...
Ancestral Dengue Virus, Malaysia | CDC EID
Estimates of Pandemic (H1N1) 2009, Beijing | CDC E...
Quinolone-Resistant Salmonella enterica | CDC EID
International Conference on Emerging Infectious Di...
Surveillance of Coccidioidomycosis, Arizona | CDC ...
Outbreaks of Influenza on Cruise Ship | CDC EID
Measles Virus Strain Diversity, Nigeria and DRC | ...
Vaccines: Vac-Gen/Shortages/main page
CDC - 2010 Haiti Cholera Outbreak
Simposio Internacional INECO 2010 de Psiquiatría
Alzheimer's Disease Neuroimaging Initiative enters...
Mouse Study Suggests Alzheimer's-Linked Protein Ca...
Where Kids Get Their Empty Calories
How Dengue Virus Infects Cells
Molecular Mimics Curb Kidney Stone Crystals
Steroids May Only Offer Short-Term Help for Tennis...
Decreasing Shigellosis-related Deaths | CDC EID
A Grandmother's Hemolytic–Uremic Syndrome | CDC EI...
Mass Fever Screening | CDC EID
Lymphotropism of MCPyV, Nova Scotia, Canada | CDC ...
Bordetella pertussis Strains, China | CDC EID
Elimination of Malaria, Comoros Archipelago | CDC ...
Salmonella enterica PFGE Clusters | CDC EID
Oropharyngeal Cancer Epidemic and HPV | CDC EID
Treatment for Malaria during Pregnancy | CDC EID
Regulatory Oversight and Safety of Probiotic Use -...
Vol. 16, No. 11 Cover: A Moveable Feast | CDC EID
Higher education tied to rare form of diabetes: Me...
MRSA Strain With Outbreak Potential Among Reports ...
Quality, Regulation and Clinical Utility of Labora...
Sentinel Initiative - Transforming How We Monitor ...
Conference on Methodological Challenges in Compara...
Identifying genetics and genomics nursing competen...
IL28B and the Control of Hepatitis C Virus Infecti...
Candidate genes versus genome-wide associations: w...
Viral hepatitis: human genes that limit infection....
Global DNA methylation levels in girls with and wi...
Family history of later-onset breast cancer, breas...
The epigenetics of (hereditary) colorectal cancer....
Epigenetic modifications and human disease. [Nat B...
Genome-wide association study identifies a psorias...
Genome-wide association analysis identifies three ...
JAMA -- Genetic Research Provides Insights Into Ag...
Common variants at TRAF3IP2 are associated with su...
Association analyses identify six new psoriasis su...
A genome-wide association study identifies new pso...
Population genetics of venous thromboembolism. A n...
Congenital Adrenal Hyperplasia and Adrenal Gland D...
Accidental drug ingestions lead to more than 100,0...
HIV/AIDS and neurologic diseases -- Karceski 75 (1...
Advanced Breast Cancers, Higher Death Rate Seen in...
CDC - Seasonal Influenza (Flu) - Questions and Ans...
Vaccines: VFC/Site Visit Questionnaire
Succimer found ineffective for removing mercury, O...
Metabolic Syndrome: From the Genetics to the Patho...
Lack of Association Between the Trp719Arg Polymorp...
Genetic Determinants of Osteoporosis: Common Bases...
Do Asian patients have worse lupus? [Lupus. 2010] ...
Recent findings on genetics of systemic autoimmune...
What can we learn from genetic studies of systemic...
The ‘omics’ of cancer
Genetic counselling for hereditary predisposition ...
SpringerLink - Journal of Genetic Counseling, Onli...
SpringerLink - Breast Cancer Research and Treatmen...
Assessment of Clinical Validity of a Breast Cancer...
Scientists Find Gene Linked To Alcoholism
Changes caused by smoking block tumour-fighting ge...
How Genes Are Selectively Silenced
Urine Test For Prostate Cancer Hopeful
NCCN 16th Annual Conference - Event Summary | Onli...
NCCN 2010 Congress Series™: Gastrointestinal Cance...
NCCN Guidelines Update Webinar Series™: Chronic My...
NCCN Webinar: Treatment Strategies for Mesotheliom...
Addition of rituximab to fludarabine and cyclophos...
New Finding Suggests Safe Surgical Margins When Re...
Air Pollution Ups Risk of Chronic Lung Disease: St...
Genetic data related to sodium-regulating hormone ...
Small BMI change in overweight children could have...
Protein injection shows promise in lowering elevat...
Treating metabolic syndrome, undergoing carotid an...
Estrogen May Boost Women's Recovery From Trauma: M...
Low-Dose Aspirin May Cut Chances of Colon Cancer: ...
Flu Meeting Highlights Latest Research: MedlinePlu...
HEPATITIS - Viral Hepatitis Updates from CDC
Perspectives on improving patient care: Genetics, ...
Potential For A Genetic Test To Predict Early Meno...
Researchers Find Key Genetic Trigger Of Depression...
First Babies Born Following Genetic Screening Stud...
In Common Childhood Obesity, Gene Variants Raise R...
Study Reveals Common Link Between Familial ALS And...
Study suggests genetic mechanisms for blood pressu...
Cancer Screening Made Simple
Four New Psoriasis 'Hotspots' Identified By U-M Ge...
Insight gained into age-related hearing loss
Genetic data related to sodium-regulating hormone ...
Orphanet Journal of Rare Diseases
New Label Changes for Commonly Prescribed HIV Drug...
Safety Alerts for Human Medical Products > Inviras...
Fight for Preemies // Bloggers Unite [english-span...
Complementary and Alternative Therapies for Back P...
Blog.AIDS.gov: What’s in it for Non-AIDS Infectiou...
NIH Recovery Act awards enable crucial health rese...
Alzheimer's Disease Neuroimaging Initiative enters...
Arch Intern Med -- Abstract: Postmenopausal Hormon...
Expression of Follicle-Stimulating Hormone Recepto...
Food-Drug Interactions-A Guide
National Guideline Clearinghouse | Supporting clie...
National Guideline Clearinghouse | Ostomy care and...
National Guideline Clearinghouse | Oral health: nu...
National Guideline Clearinghouse | Decision suppor...
National Guideline Clearinghouse | Assessment and ...
National Guideline Clearinghouse | (1) Nursing man...
National Guideline Clearinghouse | (1) Best practi...
Genetics May Play Role in Vitamin E Levels: Medlin...
Animal Study Explores Potential Gene Therapy for D...
New Tumor Marker May Improve Cancer Detection: Stu...
Ventilator Associated Pneumonia (VAP) News
HIV Transmission Through Transfusion --- Missouri ...
Hereditary Breast and Ovarian Cancer - CDC Feature...
Trastuzumab - About the Center for Drug Evaluation...
H3N2 EN SALTA - ARGENTINA - Diario HOY en la notic...
CDC Data & Statistics | Feature: Breast Cancer: Ra...
Pesticides: MedlinePlus [updated english and spani...
FDA: Include warnings on risk for class of prostat...
Safety Alerts for Human Medical Products > GnRH Ag...
Influence of Ritonavir, Alone and in Combination w...
Studies Tout Alternative HIV Regimens for Women, B...
CDC - Blogs - Safe Healthcare – First anniversary ...
Common genetic variants are significant risk facto...
Register for Next Week's Town Hall on the Future o...
Aspirin, Statins May Reduce Problems After Heart S...
Even Well-Controlled Diabetes May Present Post-Sur...
NHLBI launches body cooling treatment study for pe...
NIH funds four clinical trials to fight antimicrob...
Study Shows HRT Even Riskier Than Thought: Medline...
Low Testosterone May Raise Risk of Early Death: St...
Spontaneous Diffusion of an Effective Skin Cancer ...
Quality of Systematic Reviews of Observational Non...
2010.10.19 -- Study Shows HRT Even Riskier Than Th...
TWAS - Relevante distinción a un científico argent...
LASIK - FDA Provides Update on LASIK Quality of Li...
FDA approves Pradaxa to prevent stroke in people w...
Intestinal pseudo-obstruction - Genetics Home Refe...
Hereditary spherocytosis - Genetics Home Reference...
CDC - Blogs - Safe Healthcare – More than a Week: ...
H1N1 Unlikely to Cause Flu Pandemic in 2010-11: An...
Most measles cases in U.S. vaccine-preventable: Me...
ICSI - Cervical Cytology (Pap Test) and HPV Test i...
National Guideline Clearinghouse | Adapting your p...
National Guideline Clearinghouse | Work-related ul...
National Guideline Clearinghouse | Perioperative p...
National Guideline Clearinghouse | Part 2. Inconti...
National Guideline Clearinghouse | Part 1. Cystect...
National Guideline Clearinghouse | Updated guideli...
Human papillomavirus genotype attribution in invas...
Use of Aspirin and Other Nonsteroidal Antiinflamma...
Vaccination with a synthetic peptide from the infl...
PTEN Deficiency in Endometrioid Endometrial Adenoc...
Drosophila SPARC Is a Self-Protective Signal Expre...
RFA-AI-11-001: Tropical Medicine Research Centers ...
CDC - Blogs - Safe Healthcare – Infection Preventi...
FDA Hepatitis Update - New Baraclude (entecavir) T...
NIH-Funded Scientists Sequence Genomes of Lyme Dis...
Intervention Improves Outlook in Type 2 Diabetes
Structure of Receptor Involved in Cancer, HIV Infe...
Scientists Identify Novel Role for Lipids in Pneum...
NIH-Funded Study Finds Early HAART during TB Treat...
Kids Under 6 Account for Two-Thirds of Drug-Relate...
Two-Thirds of Spinal Fractures Undiagnosed, Untrea...
Metabolic syndrome continues to climb in the U.S.:...
Sleep problems common in arthritis patients: Medli...
Lack of sleep linked to risky colon polyps: Medlin...
Restless Legs Syndrome, Fibromyalgia Linked in Stu...
Eight virus types cause almost all cervical cancer...
GAPPKB|Home
HuGENavigator|HuGE Literature Finder|Search
IL28B Genomic-Based Treatment Paradigms for Patien...
Radiation pharmacogenomics: A genome-wide associat...
VIRUS DEL NILO OCCIDENTAL, MUERTE DE EQUINOS - ESP...
LEPTOSPIROSIS, INUNDACIONES, MUERTES - NICARAGUA (...
SALMONELLA, BROTE, TRABAJADORES HOSPITALARIOS - ES...
Early Clinical Trials With Live Biotherapeutic Pro...
Most Doctors Don't Follow Colon Cancer Screening G...
No Heart Benefit Seen From Folic Acid Supplements:...
SpringerLink - Current Hypertension Reports, Onlin...
SpringerLink - Reviews in Endocrine & Metabolic Di...
Cancer-Linked Epigenetic Effects Of Smoking Reveal...
Genetic defect found to cause severe epilepsy and ...
ADHD is a genetic disorder: Study - Health - DNA
Researchers personalize breast-cancer treatment li...
Living with Charcot-Marie-Tooth Disease: Misunders...
HSAN 1: Identification Of New Mutations Can Lead T...
13 Body Fat Distribution Genes Discovered, Some St...
Obesity Treatments Falter, But Researchers Announc...
Global Research Effort Leads To New Findings On Ge...
PLoS Medicine: Being More Realistic about the Publ...
Novel Reference Material To Standardize Gene Thera...
PHG Foundation | Structural Genomics Consortium - ...
NIH launches Genotype-Tissue Expression project, O...
KPC, MUERTES, PROPAGACIÓN RÁPIDA - BRASIL (02)
LEPTOSPIROSIS - NICARAGUA
Unexplained childhood disorders
PHG Foundation | Large-scale research into heart d...
Study Disproves Link Between Genetic Variant, Risk...
Blocking an oncogene in liver cancer could be pote...
Drug Safety and Availability > Medication Guides
Postmarket Drug Safety Information for Patients an...
Investigational New Drug Applications (INDs)-Deter...
"Leukemia, Lymphoid" - Search of: Open Studies | "...
"Leukemia, Hairy Cell" - Search of: Open Studies |...
Loss of Nutrients Following Gastric Bypass Surgery...
Low Vitality Score at Birth Associated with Cerebr...
Scientists Identify Molecular Blueprint for Lyme D...
Many With Terminal Cancer Still Getting Routine Sc...
FDA approves Botox to treat chronic migraine [2]
FDA approves Botox to treat chronic migraine
European Medicines Agency - News and press release...
European Medicines Agency - News and press release...
Shockwave therapy shows promise for tendon pain: M...
CDC - CMV: Congenital CMV Infection Trends and Sta...
National Guideline Clearinghouse | Guidelines on p...
National Guideline Clearinghouse | Evidence-based ...
National Guideline Clearinghouse | Best evidence s...
National Guideline Clearinghouse | Best evidence s...
National Guideline Clearinghouse | Best evidence s...
National Guideline Clearinghouse | Best evidence s...
International Diabetes Federation Newsletter
Gulf War Nerve Agent Tied to Late-Onset Heart Dama...
Safety Alerts for Human Medical Products > Chelati...
Drug Implant for Opioid Addiction Looks Effective:...
NIAID Media Availability: NIH Studies Influence Re...
Human progenitor cells derived from cardiac adipos...
Announcements: Conference on Mobile Technologies U...
Announcements: Final 2009--10 Influenza Season Vac...
Progress Toward Control of Rubella and Prevention ...
Tetanus and Pertussis Vaccination Coverage Among A...
Estimated Lifetime Risk for Diagnosis of HIV Infec...
National Latino AIDS Awareness Day --- October 15,...
Bacteria Identified as New Foe for Cystic Fibrosis...
FDA schedules third orphan drug workshop for Nov. ...
Weight-Loss Surgery for Teens May Be Gaining Advoc...
Danish Study Suggests Jaundice-Autism Link - Medli...
Nearly 9 percent of children experience agitation ...
Study Sees Link Between Epilepsy, Infertility - Me...
FDA MedWatch - Bisphosphonates (Osteoporosis Drugs...
Estrogen Therapy May Be Linked to Kidney Stones
Inhaled steroids don't help asthma flare-ups
Common Prostate Cancer Treatment Linked to Bone De...
Newer Therapies for Eye Disorder Not Tied to Heart...
Heart Surgery Patients Do Fine With Fewer Blood Tr...
Avastin helps in ovarian cancer but effects fade
Cancer-Fighting Bone Drugs Might Raise Stroke Risk...
Consumer Updates Possible Fracture Risk With Oste...
Drug Safety and Availability FDA Drug Safety Comm...
Revising the definition of Alzheimer's disease: a ...
Somatic Symptoms in Patients With Cancer Experienc...
Sentinel Initiative - Transforming How We Monitor ...
Guidance Documents (Medical Devices and Radiation-...
FDA approves injectable drug to treat opioid-depen...
New Evidence that Blood Clots Play a Role in Alzhe...
NIH scientists discover how dengue virus infects c...
Carotid stent has higher stroke risk than surgery:...
National Guideline Clearinghouse | Testosterone th...
National Guideline Clearinghouse | Evaluation and ...
National Guideline Clearinghouse | Endocrine treat...
Stem cell transplantation in adults - National Gui...
Primary Sclerosing Cholangitis - National Guidelin...
Pharyngitis - National Guideline Clearinghouse | G...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
View - ESMO - European Society for Medical Oncolog...
Adding Cetuximab to Chemotherapy Doubles Response ...
New Gene Tied to Deadly Ovarian Cancer
Newborn screening - Genetics Home Reference
VARICELA, BROTE ESCOLAR - COLOMBIA (PALMIRA)
MALARIA, BROTE, LLUVIAS - HONDURAS (COSTA ATLÁNTIC...
SARM, GANADO PORCINO, INFECCIÓN DURANTE BENEFICIO ...
SARM DE LA COMUNIDAD, NIÑOS, AUMENTO MARCADO - ARG...
Klebsiella pneumoniae productora de betalactamasa ...
Testing of VKORC1 and CYP2C9 alleles to guide warf...
Routine dihydropyrimidine dehydrogenase testing fo...
Consumers’ Use of Web-Based Information and Their ...
SCIENCE REPORT - octubre 2010 -
Uptake of Huntington disease predictive testing in...
A genome-wide meta-analysis identifies novel loci ...
Current developments and controversies: does the s...
Genome-wide association study of increasing suicid...
Personalized Medicine in Non-Small-Cell Lung Cance...
Pharmacogenomics: role in medicines approval and c...
KRAS mutational analysis for colorectal cancer
Genetic Testing for CYP450 Polymorphisms to Predic...
Women's Health Highlights [4]: Ovarian Cancer - Re...
Women's Health Highlights [3]: Cervical Cancer - R...
Women's Health Highlights [2]: Breast Cancer - Ca...
Women's Health Highlights [1]: Cardiovascular Dise...
The Relationship Between the Emergent Primary Perc...
Germline genetic markers for urinary bladder cance...
Longitudinal Changes in Patient Distress following...
Maternal polymorphisms in folic acid metabolic gen...
Studies with Wnt genes and nonsyndromic cleft lip ...
Genome-wide association study (GWAS)-identified di...
Genomics of ankylosing spondylitis. [Discov Med. 2...
Gene variations that alter key enzyme linked to pr...
Colonoscopy may miss more than 7 percent of cancer...
Cancer May Run in Families of Young Breast Cancer ...
Big Waist Raises Risk of Diabetes, Analysis Sugges...
Diabetes Complications - What to do in a Medical E...
Influenza Activity --- United States and Worldwide...
CDC - Seasonal Influenza (Flu) - Vaccination Cover...
MALARIA, P. VIVAX, CASO AUTÓCTONO - ESPAÑA (ARAGÓN...
TUBERCULOSIS, BROTE NOSOCOMIAL, TRABAJADORES - PUE...
VNO, NUEVO CASO HUMANO - ESPAÑA (ANDALUCIA)
CDC - Seasonal Influenza (Flu) - Final Season Vacc...
About the Center for Drug Evaluation and Research ...
Race Doesn't Seem to Predict Lung Cancer Survival ...
Finding the words: new brain stimulation technique...
Laboratory Study Shows Turmeric May Have Bone-Prot...
Safety Alerts for Human Medical Products > Meridia...
Abbott Laboratories agrees to withdraw its obesity...
Mammogram Guidelines Still Beget Confusion: Medlin...
Heartburn Drugs, Plavix Seem Safe to Take Together...
Early versus delayed treatment of relapsed ovarian...
Abstract | Improved healing response in delayed un...
Vaccines: ACIP/Meetings, Agendas, Dates, Registrat...
Thirst for excitement is hidden in your genes
Revealing New Twists In Double Helix Discovery Sto...
New Functions For New Genes, Non-coding RNAs Get I...
'RaDiCAL' Approach To Gene Discovery Opens Doors T...
Discovery Of New Class Of Objects Encoded Within T...
DNA Art Imitates Life: Construction Of A Nanoscale...
A genetic view of ADHD
Brain Region May Link Gene With Risk of Bipolar Di...
PHG Foundation | Large rare copy number variants i...
PHG Foundation | Gene implicated in male fertility...
Chromosomal Break Gives Scientists A Break In Find...
Study Of Twins Provide Clue That Genetic Epilepsy ...
Einstein Scientist And HHMI Investigator Awarded $...
Epigenome effort makes its mark : Nature News
Researchers Pool Data To Search For Genetic Risks ...
Researchers Discover Genetic Changes That Make Som...
Radiation pharmacogenomics identifies biomarkers t...
Genomics|About|Funding|2010 CDC and NIH New Genomi...
e-boletín Drogas y Medicamentos N° 9
National Guideline Clearinghouse | Guideline Synth...
Celiac Disease - National Guideline Clearinghouse ...
National Guideline Clearinghouse | Lung cancer and...
National Guideline Clearinghouse | Interstitial lu...
National Guideline Clearinghouse | Cough. In: Pulm...
National Guideline Clearinghouse | COPD – Chronic ...
National Guideline Clearinghouse | Asthma. In: Pul...
NIH Grantee Wins 2010 Nobel Prize in Chemistry, Oc...
NIH announces new program to accelerate research i...
NIH funds advanced development of three biodefense...
NIH launches Genotype-Tissue Expression project, O...
Study details structure of potential target for HI...
Estudio halla clave sobre presión arterial elevada...
RESISTENCIA BACTERIANA, MAL USO DE ANTIBIÓTICOS - ...
EMPONZOÑAMIENTO OFÍDICO, AUMENTO: EMERGENCIA SANIT...
SARAMPIÓN, BROTE, CASOS CONFIRMADOS - ARGENTINA (B...
VIRUS CHIKUNGUNYA, CASOS AUTÓCTONOS - FRANCIA (VAR...
VIRUS DE LA HEPATITIS B, ORIGEN, AVES PRE-HISTÓRIC...
DIFTERIA, NUEVOS CASOS, ALERTA SANITARIA - BOLIVIA...
European Medicines Agency - News and press release...
Advancing Regulatory Science > Advancing Regulator...
Noscira finaliza el reclutamiento de su estudio en...
NCCN Educational Opportunities: NCCN 2010 Patient ...
NCCN Educational Opportunities: An Overview of Ste...
NCCN Webinar: Maintenance Therapy for Non-Small Ce...
NCCN Webinar: Treatment Strategies for Mesotheliom...
NCCN Educational Opportunities: Kidney Cancer Sess...
NCCN Guidelines Update Webinar Series™: Chronic My...
National Guideline Clearinghouse | Rapid response ...
National Guideline Clearinghouse | Preventive serv...
National Guideline Clearinghouse | Preventive serv...
National Guideline Clearinghouse | Immunizations.
LUPUS - Could I Have Lupus? : Home
- La primera vacuna española contra el Alzheimer c...
This Week in The Journal -- 30 (37): i -- Journal ...
Pathogenic Lysosomal Depletion in Parkinson's Dise...
Farmacogenética: una realidad clínica :: El Médico...
National Guideline Clearinghouse | Topotecan for t...
National Guideline Clearinghouse | Topotecan for t...
National Guideline Clearinghouse | Sunitinib for t...
National Guideline Clearinghouse | Prasugrel for t...
National Guideline Clearinghouse | Pemetrexed for ...
Evidence-Based Clinical Recommendations Regarding ...
CAHPS Clinician & Group Survey
CDC - Seasonal Influenza (Flu) - Q & A: Seasonal I...
Alternate Therapy for Poorly Controlled Asthma
Stress Hormone Causes Epigenetic Changes
Epigenome Varies With Body Mass Index
Salmonella Are Armed, Agile and Primed for Invasio...
Immunotherapy Boosts Pediatric Cancer Survival
El padre de la fecundacion in vitro Robert Edwards...
National prevalence and risk factors for food alle...
Children, males and blacks are at increased risk f...
NIH blood pressure trial expands to include more o...
Human Growth Hormone Shows Promise in Treating Cys...
Kids With Allergies Shouldn't Skip Flu Shots, Expe...
New Clues to Treating Ovarian Cancer Relapse - Nue...
Antibiotics for Viral Respiratory Infections in Ho...
Data Sources for Gender Research - Women's Health ...
Women and Medications - Women's Health Highlights:...
Health Care Quality and Safety - Women's Health Hi...
Health Impact of Violence Against Women - Women's ...
Mental/Behavioral Health - Women's Health Highligh...
Chronic Illness and Care - [Diabetes] Women's Heal...
Hysterectomy - Women's Health Highlights: Recent F...
Birth Outcomes - Women's Health Highlights: Recent...
Reproductive Health - Women's Health Highlights: R...
WOMEN´s CANCER - Women's Health Highlights: Recent...
Women's Health Highlights: Recent Findings
A Systematic Review of the Effect of CYP3A5 Genoty...
Pharmacogenomic implications of variants of monoam...
A Large-Scale, Consortium-Based Genomewide Associa...
GAPPKB|Home
HuGENavigator|HuGE Literature Finder|Search
Pharmacogenomics and active surveillance for serio...
Pharmacogenomics in pediatric leukemia. [Curr Opin...
Informa Healthcare - Australasian Psychiatry - 18(...
Pharmacogenomics instruction in US and Canadian me...
FDA Clinical Investigator Training Course
Advisory Committee Calendar > November 3, 2010: Jo...
Workshops, Meetings & Conferences (Biologics) > Pu...
Advisory Committee Calendar > Meeting of the Trans...
Advisory Committee Calendar > October 18, 2010: Ca...
Accelerating Therapies for Rare Diseases Workshop
TIP 52: Clinical Supervision and Professional Deve...
TIP 51: Substance Abuse Treatment: Addressing the ...
Interview with a Woman Fighting Breast Cancer, Jea...
TIP 50: Addressing Suicidal Thoughts and Behaviors...
Researchers Uncover Tuberculosis' Genomic Signatur...
PHG Foundation | Boost for international proteomic...
Diving deeper into the gene pool: Innovative softw...
Research Demonstrates Progress Towards DNA Strand ...
Results Of Global Team's Investigation Into The Ge...
Genetic differences in sense of smell identified t...
New gene associated with increased risk of Alzheim...
Reuters Health Information (2010-09-29): Could gen...
First direct evidence that ADHD is a genetic disor...
Genetic Cause For Migraine Found
Identification Of Key Action Of A Gene Linked To B...
Structural Genomics Consortium releases 1 000th pr...
Researchers Create First Molecule Able To Block Ke...
Be connected, be informed | www.eurordis.org [engl...
BURQOL-RD Project | www.eurordis.org [english-span...
LOS DERECHOS DE LOS PACIENTES EN RELACIÓN CON LOS ...
Progestin intrauterine device and GnRH analogue fo...
Genetic Factor In Osteoporosis Discovered
City-living Helped Us Evolve Immunity To Disease
Genetic ancestry: A new look at racial disparities...
Study Finds Gene Associated With Aggressive Skin C...
Researchers report MALAT1 gene regulates pre-mRNA ...
A New Way Of Reversing Certain Cancers
Accident led to cancer treatment for 'Philadelphia...
Women With Both Triple Negative Breast Cancer And ...
Genomics|Resources|Diseases|Breast and Ovarian Can...
2010 CAHPS Clinician & Group Survey Database Updat...
Genetic Glitch Tied to Disrupted Sperm Production:...
ESTRADIOL - NEW from FDA - VIDEO
MedWatch Safety Information Resources for Busy Phy...
Conference on Methodological Challenges in Compara...
NIH grants will advance studies of the form and fu...
Addition of immunotherapy boosts pediatric cancer ...
NCBI launches the Database of Genomic Structural V...
NIH Transformative Research Project Awards hasten ...
Lifestyle intervention improves risk factors in ty...
NIH scientists describe how salmonella bacteria sp...
Gene Disorder Linked to ADHD
Carla Nieto Madrid - Aprobado un nuevo fármaco par...
Ácido aminolevulínico y Canikinumab aprobados en E...
Neurology.org
Nationwide implementation of adjunctive dexamethas...

►  septiembre (561)
►  agosto (468)
►  julio (489)
►  junio (463)
►  mayo (615)
►  abril (504)
►  marzo (510)
►  febrero (345)
►  enero (510)

►  2009 (4504)